



Press Release

TheraPPI Bioscience awarded a Fongit Innovation Fund (FIF) seed loan

The Fondation Genevoise pour l'Innovation Technologique ("FONGIT") has granted a FIF seed loan of CHF100 000 to TheraPPI Bioscience which is currently being registered in the Canton of Geneva (Switzerland) for their innovative work on modifying protein interactions to offer treatments for drug-resistant cancers and non-curable rare diseases.

November 17, 2023 – Lyon, France

- ends -

Notes:

About FONGIT (<https://www.fongit.ch/>) :

The “Fondation Genevoise pour l’Innovation Technologique” – FONGIT, is Switzerland’s premier innovation platform supporting innovative tech ventures in Geneva.

Founded in 1991, FONGIT has an excellent track record of building successful companies and is a private, non-profit foundation, benefitting from the support of the State of Geneva (Switzerland). FONGIT’s mission is to transform technological innovation into social and economic value in the Geneva region.

About TheraPPI Bioscience :

TheraPPI is preclinical-stage biotech company which develops protein interaction-modifying drugs to offer patients better treatments. TheraPPI has been incubated within Pulsalys (French TTO of Lyon-St Etienne).

TheraPPI’s two first programs target a novel MAPK protein interaction discovered by the founder team at the CRCL (University Claude Bernard Lyon 1, Inserm, Centre Léon Bérard and CNRS) in Lyon, France, in collaboration with the C3D technology platform of Lyon (Centre for Drug Discovery and Development) and with the support of Hospices Civils de Lyon..

The prognosis of patients with advanced cancers remains poor. The MAPK signaling is hyperactivated in over 40% of human cancers and MAPK-activating mutations cause rare diseases. The efficacy of current MAPK Inhibitors is undercut by cancer resistance and by their inability to cure these rare diseases.

TheraPPI’s lead program in oncology revolutionizes RAS-MAPK targeting: the new mode of action leverages three mechanisms with direct killing cancer cells, no resistance induction and activation of an anti-tumoral immune response.

TheraPPI’s lead program aims to obtain a high rate of clinical responses, to circumvent cancer resistance and to improve the response of immunotherapies and thus to offer a better prognosis to patients with advanced cancer.

Read more: <https://tppibio.com/>

Follow us on LinkedIn: <https://www.linkedin.com/therappi-bioscience/>

Forward Looking Statements:

This press release includes forward-looking statements and assumptions which reflect the management’s current views of future events and operations. These forward-looking statements involve certain significant risks and uncertainties, and actual results may (negatively or positively) differ substantially from the forward-looking statements described explicitly or implicitly by TheraPPI.

Contacts:

TheraPPI Bioscience

Luc Otten

CEO and co-founder

info@tppibio.com